| DEBT
|
|
|
|
|
|
|
1.DESCRIPTION OF BUSINESS
Diplomat Pharmacy, Inc. and its consolidated subsidiaries (the “Company”) operate a specialty pharmacy business which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. Its primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, HIV and many other serious or long-term conditions. The Company has its corporate headquarters and main distribution facility in Flint, Michigan and maintains 16 other pharmacy locations in Arizona, California, Connecticut, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, North Carolina, Ohio and Pennsylvania. The Company also has centralized call centers to effectively deliver services to customers located in all 50 states in the United States of America (“U.S.”) and U.S. territories. The Company operates as one reportable segment.
Initial Public Offering
In October 2014, the Company completed its initial public offering (“IPO”) in which 15,333,333 shares of common stock were sold at a public offering price of $13.00 per share. The Company sold 11,000,000 shares of common stock and certain shareholders sold 4,333,333 shares of common stock. The Company did not receive any proceeds from the sale of common stock by the shareholders. The Company received net proceeds of $130,440 after deducting underwriting discounts and commissions of $9,652, and other offering expenses of $2,908. Proceeds of $80,458 were used to repay existing indebtedness to certain current or former shareholders and employees ($19,824), and borrowings under the line of credit ($60,634). The remaining proceeds were used for working capital and other general corporate purposes.
Immediately prior to the closing of the IPO, each share of the Company’s then-outstanding capital stock converted into one share of its newly-authorized shares of no par value common stock.
Follow-On Public Offering
In March 2015, the Company completed a follow-on public offering in which 9,821,125 shares of common stock were sold at a public offering price of $29.00 per share. The Company sold 6,821,125 shares of common stock and certain shareholders sold 3,000,000 shares of common stock. The Company did not receive any proceeds from the sale of common stock by the shareholders. The Company received net proceeds of $187,238 after deducting underwriting discounts and commissions of $9,891, and other offering expenses of $685. The Company used $36,298 of the net proceeds to repurchase options to purchase common stock held by a number of current and former employees, including certain executive officers, with the remainder of the proceeds used to pay a portion of the cash consideration for the BioRx, LLC (“BioRx”) acquisition (Note 4). The purchase price for each stock option repurchased was based on the public offering price per share, net of the underwriting discount and exercise price.
|
2.BASIS OF PRESENTATION
Interim Unaudited Condensed Consolidated Financial Statements
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the interim financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the financial position, results of operations, cash flows and changes in shareholders’ equity. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 3, 2015.
Stock Split
In October 2014, immediately prior to the completion of the IPO, the Board of Directors declared and approved a 8,500-for-one stock split, effected in the form of a stock dividend, on each share of common stock outstanding to the common shareholders of record. Accordingly, all share and per share amounts in these unaudited condensed consolidated financial statements and notes thereto, were adjusted, where applicable, to reflect the stock split on a retroactive basis.
Effect of Conversion from S Corporation to C Corporation
On January 23, 2014, the Company changed its income tax status from an S corporation to a C corporation. Accordingly, on that date, the Company recorded a net deferred income tax liability of $2,965 and a charge to income tax expense for the same amount. The Company reclassified its accumulated deficit, inclusive of the net deferred tax liability adjustment, into additional paid-in capital on the date of conversion.
Reclassifications
Certain items in the prior periods’ financial statements have been reclassified to conform to the current presentation.
|
3.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The condensed consolidated financial statements include the accounts of Diplomat Pharmacy, Inc., its wholly-owned subsidiaries, and a 51%-owned subsidiary, formed in August 2014, which the Company controls (see Note 7). The Company also owns a 25% interest in a non-consolidated entity which is accounted for under the equity method of accounting since the Company does not control the entity but has the ability to exercise significant influence over its operating and financial policies. This equity method investment was fully impaired during the fourth quarter of 2014. An investment in an entity in which the Company owns less than 20% and does not have the ability to exercise significant influence is accounted for under the cost method.
Noncontrolling interest in a consolidated subsidiary in the condensed consolidated balance sheets represents the minority shareholders’ proportionate share of the equity in such subsidiary. Consolidated net income (loss) is allocated to the Company and noncontrolling interests (i.e., minority shareholders) in proportion to their percentage ownership.
All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.
Revenue Recognition
The Company recognizes revenue from prescription drug sales for home delivery at the time the drugs are shipped. At the time of shipment, the Company has performed substantially all of its obligations under its payor contracts and does not experience a significant level of returns or reshipments. If the Company administers a drug treatment regimen in a patient’s home, the Company recognizes revenue at the time of administration. Revenues from dispensing specialty prescriptions that are picked up by patients at an open door or retail pharmacy location are recorded at prescription adjudication, which approximates the fill date. Sales taxes are presented on a net basis (excluded from revenues and costs). Revenues generated from prescription drug sales were $941,533 and $592,410 for the three months ended September 30, 2015 and 2014, respectively, and $2,365,860 and $1,594,197 for the nine months ended September 30, 2015 and 2014, respectively.
The Company recognizes revenue from service, data and consulting services when the services have been performed and the earnings process is therefore complete. Revenues generated from service, data and consulting services were $5,380 and $3,119 for the three months ended September 30, 2015 and 2014, respectively, and $13,947 and $8,684 for the nine months ended September 30, 2015 and 2014, respectively.
New Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which will supersede the existing revenue recognition guidance under U.S. GAAP. The new standard focuses on creating a single source of revenue guidance for revenue arising from contracts with customers for all industries. The objective of the new standard is for companies to recognize revenue when it transfers the promised goods or services to its customers at an amount that represents what the company expects to be entitled to in exchange for those goods or services. In July 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606) Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 by one year to annual reporting periods beginning after December 15, 2017 for public entities. ASU 2014-09 may be applied either retrospectively or as a cumulative effect adjustment as of the date of adoption. Early adoption is not permitted. The Company is currently assessing the method under which it will adopt and the potential impact of adopting ASU 2014-09 on its financial position, results of operations, cash flows and/or disclosures.
In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Targets Could Be Achieved after the Requisite Service Period, requiring that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This ASU is effective within annual periods beginning on or after December 15, 2015, including interim periods within that reporting period. The Company does not expect the adoption of this guidance to have a significant impact on its financial position, results of operations, cash flows or disclosures.
In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), and, in August 2015, the FASB issued ASU No. 2015-15, Interest — Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-15 then clarified that debt issuance costs related to a line-of-credit arrangement can be presented as an asset on the balance sheet, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. These ASUs are effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. An entity should apply this new guidance on a retrospective basis and is required to comply with applicable disclosures for a change in an accounting principle. These standards will result in a balance sheet reclassification and require related disclosure revisions in the Company’s financial statements.
In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective within annual periods beginning on or after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.
In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, requiring that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This ASU also requires an entity to present separately on the face of the income statement, or disclose in the notes to the financial statements, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This ASU is effective within annual periods beginning on or after December 15, 2015, including interim periods within that reporting period, and will be applied prospectively to measurement-period adjustments that occur after the effective date of this ASU.
|
4.BUSINESS ACQUISITIONS
The Company accounts for its business acquisitions using the acquisition method as required by FASB Accounting Standards Codification Topic 805, Business Combinations. The Company ascribes significant value to the synergies and other benefits that do not meet the recognition criteria of acquired identifiable intangible assets. Accordingly, the value of these components is included within goodwill. The Company’s business acquisitions described below were treated as stock purchases for accounting purposes, and — except for one subsidiary of BioRx — the acquisitions were treated as asset purchases for income tax purposes and the related goodwill resulting from these business acquisitions is deductible for tax purposes. The results of operations for acquired businesses are included in the Company’s consolidated financial statements from their respective acquisition dates.
Burman’s Apothecary, LLC
On June 19, 2015, the Company acquired all of the outstanding equity interests of Burman’s Apothecary, LLC (“Burman’s”). Burman’s, located in the greater Philadelphia, Pennsylvania area, is a provider of individualized patient care with a primary focus on hepatitis C. The Company acquired Burman’s to further expand its existing hepatitis business and to increase its national presence. The following table summarizes the consideration transferred to acquire Burman’s:
Cash at closing |
|
$ |
84,296 |
|
253,036 restricted common shares |
|
9,578 |
|
|
Receivable for post-closing adjustment |
|
(6,880 |
) |
|
|
|
|
|
|
|
|
$ |
86,994 |
|
|
|
|
|
|
The above share consideration is based on 253,036 shares, as computed in accordance with the purchase agreement, multiplied by the per share closing market price as of June 18, 2015 ($42.06) and multiplied by 90% to account for the restricted nature of the shares.
The Company incurred acquisition-related costs of $532 and $735 which were charged to “Selling, general and administrative expenses” during the three and nine months ended September 30, 2015, respectively.
The following table summarizes the preliminary amounts of identifiable assets acquired and liabilities assumed at the acquisition date:
Accounts receivable |
|
$ |
17,109 |
|
Inventories |
|
8,668 |
|
|
Prepaid expenses and other current assets |
|
7,514 |
|
|
Property and equipment |
|
88 |
|
|
Capitalized software for internal use |
|
17,000 |
|
|
Definite-lived intangible assets |
|
23,400 |
|
|
Accounts payable |
|
(25,761 |
) |
|
Accrued expenses — compensation and benefits |
|
(169 |
) |
|
Accrued expenses — other |
|
(6 |
) |
|
|
|
|
|
|
Total identifiable net assets |
|
47,843 |
|
|
Goodwill |
|
39,151 |
|
|
|
|
|
|
|
|
|
$ |
86,994 |
|
|
|
|
|
|
Definite-lived intangible assets that were acquired and their respective useful lives are as follows:
|
|
Useful |
|
Amount |
|
|
Physician relationships |
|
10 years |
|
$ |
15,000 |
|
Non-compete employment agreements |
|
5 years |
|
5,700 |
|
|
Favorable supply agreement |
|
1 year |
|
2,700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
23,400 |
|
|
|
|
|
|
|
|
The Company has not finalized the purchase price allocation. Accordingly, the purchase price allocation described above could change materially as the Company finalizes its assessment of the allocation and the fair values of the net tangible and intangible assets it acquired. The Company determined the estimated fair values of the identifiable long-lived assets with assistance from an independent valuation firm.
BioRx
On February 26, 2015, the Company signed a definitive agreement to acquire BioRx. On April 1, 2015, the Company acquired BioRx, a highly specialized pharmacy and infusion services company based in Cincinnati, Ohio that provides treatments for patients with ultra-orphan and rare, chronic diseases. The Company acquired BioRx to further expand its existing specialty infusion business and to increase its national presence. The following table summarizes the consideration transferred to acquire BioRx:
Cash |
|
$ |
217,024 |
|
4,038,853 restricted common shares |
|
125,697 |
|
|
Contingent consideration at fair value |
|
41,000 |
|
|
|
|
|
|
|
|
|
$ |
383,721 |
|
|
|
|
|
|
The above share consideration at closing is based on 4,038,853 shares, as computed in accordance with the purchase agreement, multiplied by the per share closing market price as of March 31, 2015 ($34.58) and multiplied by 90% to account for the restricted nature of the shares.
The purchase price includes a contingent consideration arrangement that requires the Company to issue up to 1,350,309 shares of its restricted common stock, as computed in accordance with the purchase agreement, to the former holders of BioRx’s equity interests based upon the achievement of a certain earnings before interest, taxes, depreciation and amortization target in the twelve month period ending March 31, 2016. Payment of the contingent consideration is subject to acceleration at the maximum contingent amount in the event of (i) a change in control of the Company or (ii) the termination without cause of either of two principals of BioRx that have continued employment with the Company following the closing, in each case during the 12-month period ending March 31, 2016.
The Company incurred acquisition-related costs of $40 and $1,394 which were charged to “Selling, general and administrative expenses” during the three and nine months ended September 30, 2015, respectively.
The following table summarizes the preliminary amounts of identifiable assets acquired and liabilities assumed at the acquisition date:
Cash and cash equivalents |
|
$ |
1,786 |
|
Accounts receivable |
|
38,946 |
|
|
Inventories |
|
5,546 |
|
|
Deferred income taxes |
|
382 |
|
|
Prepaid expenses and other current assets |
|
287 |
|
|
Property and equipment |
|
494 |
|
|
Definite-lived intangible assets |
|
181,700 |
|
|
Other noncurrent assets |
|
163 |
|
|
Accounts payable |
|
(25,088 |
) |
|
Accrued expenses — compensation and benefits |
|
(1,653 |
) |
|
Accrued expenses — other |
|
(852 |
) |
|
Deferred income taxes |
|
(9,117 |
) |
|
|
|
|
|
|
Total identifiable net assets |
|
192,594 |
|
|
Goodwill |
|
191,127 |
|
|
|
|
|
|
|
|
|
$ |
383,721 |
|
|
|
|
|
|
Definite-lived intangible assets that were acquired and their respective useful lives are as follows:
|
|
Useful |
|
Amount |
|
|
Patient relationships |
|
10 years |
|
$ |
130,000 |
|
Non-compete employment agreements |
|
5 years |
|
39,700 |
|
|
Trade names and trademarks |
|
8 years |
|
12,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
181,700 |
|
|
|
|
|
|
|
|
The Company has not finalized the purchase price allocation. Accordingly, the purchase price allocation described above could change materially as the Company finalizes its assessment of the allocation and the fair values of the net tangible and intangible assets it acquired. The Company determined the estimated fair values of the identifiable long-lived assets with assistance from an independent valuation firm. The valuation firm also assisted with the Company’s determination of the fair value of the contingent consideration utilizing a Monte Carlo simulation. Based on a decrease in the Company’s stock price since BioRx’s acquisition, the fair value of this contingent consideration liability decreased to $38,000 as of September 30, 2015.
MedPro Rx, Inc.
On June 27, 2014, the Company acquired all of the authorized, issued and outstanding shares of capital stock of MedPro Rx, Inc. (“MedPro”). MedPro, based in Raleigh, North Carolina, is a specialty pharmacy focused on specialty infusion therapies including hemophilia and immune globulin. The Company acquired MedPro to expand its existing specialty infusion business and to increase its presence in the mid-Atlantic and Southern regions of the U.S.
The Company did not acquire MedPro’s affiliate from which MedPro leased certain operating and other facilities. Instead, the Company, commensurate with the acquisition, entered into a five-year external lease agreement for the facilities on similar terms. As the Company does not direct the significant activities of the lessor, it is not consolidated into the Company’s financial statements.
The Company incurred acquisition-related costs of $190 and $825 which were charged to “Selling, general and administrative expenses” during the three and nine months ended September 30, 2014.
The following table summarizes the consideration transferred to acquire MedPro:
Cash |
|
$ |
52,267 |
|
716,695 restricted common shares |
|
12,000 |
|
|
Contingent consideration at fair value |
|
4,270 |
|
|
|
|
|
|
|
|
|
$ |
68,537 |
|
|
|
|
|
|
The purchase price includes a contingent consideration arrangement that requires the Company to pay the former owners an additional payout based upon the achievement of certain revenue and gross profit targets in each of the twelve month periods ending June 30, 2015 and 2016. The maximum payout of contingent consideration is $11,500. Approximately $3,500 of the purchase consideration was deposited into an escrow account to be held for two years after the closing date to satisfy any of the Company’s indemnification claims.
The following table summarizes the amounts of identifiable assets acquired and liabilities assumed at the acquisition date:
Cash and cash equivalents |
|
$ |
668 |
|
Accounts receivable |
|
9,050 |
|
|
Inventories |
|
3,819 |
|
|
Prepaid expenses and other current assets |
|
204 |
|
|
Property and equipment |
|
697 |
|
|
Capitalized software for internal use |
|
25 |
|
|
Definite-lived intangible assets |
|
37,099 |
|
|
Accounts payable |
|
(3,638 |
) |
|
Accrued expenses — compensation and benefits |
|
(157 |
) |
|
Accrued expenses — other |
|
(865 |
) |
|
|
|
|
|
|
Total identifiable net assets |
|
46,902 |
|
|
Goodwill |
|
21,635 |
|
|
|
|
|
|
|
|
|
$ |
68,537 |
|
|
|
|
|
|
Definite-lived intangible assets that were acquired and their respective useful lives are as follows:
|
|
Useful |
|
Amount |
|
|
Patient relationships |
|
7 years |
|
$ |
24,000 |
|
Trade names and trademarks |
|
10 years |
|
8,700 |
|
|
Non-compete employment agreements |
|
5 years |
|
4,399 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
37,099 |
|
|
|
|
|
|
|
|
The Company determined the fair values of the identifiable long-lived assets with assistance from an independent valuation firm. The valuation firm also assisted with the Company’s determination of the fair value of the contingent consideration utilizing historical results, forecasted operating results of MedPro for each of the twelve month periods ending June 30, 2015 and 2016, and the corresponding contractual contingent payouts based on those results discounted at rates commensurate with the uncertainty involved. Based on operating results since MedPro’s acquisition, the Company increased the estimated contingent payment in the fourth quarter of 2014, and, with accreted interest through September 30, 2015, the resulting liability as of September 30, 2015 was $5,316. Based upon MedPro’s actual results for the twelve months ended June 30, 2015, $5,750 was earned and was paid during the third quarter of 2015.
Proforma Operating Results
The following unaudited pro forma summary presents consolidated financial information as if the Burman’s, BioRx and MedPro acquisitions had occurred on January 1, 2014. The unaudited pro forma results reflect certain adjustments related to the acquisitions, such as amortization expense resulting from intangible assets acquired and adjustments to reflect the Company’s borrowings and tax rates. Accordingly, such pro forma operating results were prepared for comparative purposes only and do not purport to be indicative of what would have occurred had the acquisitions been made as of January 1, 2014 or of results that may occur in the future.
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
|
||||
Net sales |
|
$ |
946,913 |
|
$ |
733,776 |
|
$ |
2,656,523 |
|
$ |
2,055,904 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to Diplomat Pharmacy, Inc. |
|
$ |
11,090 |
|
$ |
5,536 |
|
$ |
29,259 |
|
$ |
11,565 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share — basic |
|
$ |
0.17 |
|
$ |
0.13 |
|
$ |
0.47 |
|
$ |
0.27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share — diluted |
|
$ |
0.17 |
|
$ |
0.12 |
|
$ |
0.46 |
|
$ |
0.26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.FAIR VALUE MEASUREMENTS
The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy was established, which prioritizes the inputs used in measuring fair value as follows:
Level 1:Observable inputs such as quoted prices in active markets;
Level 2:Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.
Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques:
A. |
Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. |
B. |
Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost). |
C. |
Income approach: Techniques to convert future amounts to a single present amount based upon market expectations (including present value techniques, option-pricing and excess earnings models). |
The following table presents the placement in the fair value hierarchy of assets and liabilities that are measured and disclosed at fair value on a recurring basis at September 30, 2015 and December 31, 2014:
|
|
Asset / |
|
|
|
Valuation |
|
||
|
|
(Liability) |
|
Level 3 |
|
Technique |
|
||
September 30, 2015: |
|
|
|
|
|
|
|
||
Contingent consideration |
|
$ |
(44,281 |
) |
$ |
(44,281 |
) |
C |
|
|
|
|
|
|
|
|
|
||
December 31, 2014: |
|
|
|
|
|
|
|
||
Contingent consideration |
|
$ |
(11,691 |
) |
$ |
(11,691 |
) |
C |
|
The following table sets forth a roll forward of the Level 3 measurements:
|
|
Contingent |
|
|
Balance at January 1, 2015 |
|
$ |
(11,691 |
) |
BioRx acquisition |
|
(41,000 |
) |
|
Changes in fair value |
|
1,660 |
|
|
Payments |
|
6,750 |
|
|
|
|
|
|
|
Balance at September 30, 2015 |
|
$ |
(44,281 |
) |
|
|
|
|
|
The carrying amounts of the Company’s financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, accounts payable and other liabilities, approximate their estimated fair values due to the relative short-term nature of the amounts. The carrying amount of debt approximates fair value due to variable interest rates at customary terms and rates the Company could obtain in current financing.
|
6.INVENTORIES
Inventories consist of the following:
|
|
September 30, |
|
December 31, |
|
||
|
|
2015 |
|
2014 |
|
||
Prescription medications, over-the-counter medications and medical supplies, and non-medical retail items |
|
$ |
153,286 |
|
$ |
110,464 |
|
Raw materials |
|
— |
|
208 |
|
||
Finished goods |
|
7 |
|
11 |
|
||
|
|
|
|
|
|
||
|
|
$ |
153,293 |
|
$ |
110,683 |
|
|
|
|
|
|
|
|
|
|
7.GOODWILL AND OTHER INTANGIBLE ASSETS
The following table sets forth a roll forward of goodwill for the nine months ended September 30, 2015:
Balance at January 1, 2015 |
|
$ |
23,148 |
|
BioRx acquisition |
|
191,127 |
|
|
Burman’s acquisition |
|
39,151 |
|
|
|
|
|
|
|
Balance at September 30, 2015 |
|
$ |
253,426 |
|
|
|
|
|
|
Definite-lived intangible assets consist of the following:
|
|
September 30, 2015 |
|
December 31, 2014 |
|
||||||||||||||
|
|
Gross |
|
Accumulated |
|
Net |
|
Gross |
|
Accumulated |
|
Net |
|
||||||
Patient relationships |
|
$ |
159,100 |
|
$ |
(11,507 |
) |
$ |
147,593 |
|
$ |
29,100 |
|
$ |
(2,895 |
) |
$ |
26,205 |
|
Non-compete employment agreements |
|
50,399 |
|
(5,612 |
) |
44,787 |
|
4,999 |
|
(560 |
) |
4,439 |
|
||||||
Trade names and trademarks |
|
22,100 |
|
(2,082 |
) |
20,018 |
|
10,100 |
|
(575 |
) |
9,525 |
|
||||||
Physician relationships |
|
15,000 |
|
(438 |
) |
14,562 |
|
— |
|
— |
|
— |
|
||||||
Software licensing agreement |
|
2,647 |
|
— |
|
2,647 |
|
2,647 |
|
— |
|
2,647 |
|
||||||
Favorable supply agreement |
|
2,700 |
|
(787 |
) |
1,913 |
|
— |
|
— |
|
— |
|
||||||
Intellectual property |
|
2,157 |
|
— |
|
2,157 |
|
2,157 |
|
— |
|
2,157 |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
$ |
254,103 |
|
$ |
(20,426 |
) |
$ |
233,677 |
|
$ |
49,003 |
|
$ |
(4,030 |
) |
$ |
44,973 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense was $7,908 and $1,725 for the three months ended September 30, 2015 and 2014, respectively, and $16,396 and $2,353 for the nine months ended September 30, 2015 and 2014, respectively.
On August 28, 2014, the Company and two unrelated third party entities entered into a contribution agreement to form a new company, Primrose Healthcare, LLC (“Primrose”). Primrose functions as a management company, managing a network of physicians and medical professionals providing continuum care for patients infected with the hepatitis C virus. The Company contributed $5,000 for its 51% interest, of which $2,000 and $3,000 were contributed in 2015 and 2014, respectively. The unrelated third party entities contributed a software licensing agreement valued at $2,647 and intellectual property valued at $2,157. No amortization related to these intangibles has been recorded as the entity has yet to recognize any revenue.
|
8.INVESTMENT IN NON-CONSOLIDATED ENTITIES
In October 2011, the Company purchased a 25% minority interest in WorkSmartMD, L.L.C., also known as Ageology, for $5,000 of cash consideration, which was paid in installments during 2011, 2012 and 2013. During November and December 2013, the Company entered into two $1,000 6% per annum interest-bearing promissory notes receivable from Ageology. During January 2014, the Company entered into a $500, 8% per annum interest bearing secured promissory note receivable from Ageology. The notes are due on demand and secured by all personal property and fixtures owned by Ageology. In addition, in transactions unrelated to the Company, an affiliated entity owned by the Company’s chief executive officer has personally loaned $8,725 to Ageology as of September 30, 2015.
During the fourth quarter of 2014, the Company reassessed the recoverability of its investment in Ageology. Based upon this assessment, it was determined that a full impairment was warranted, primarily due to updated projections of continuing losses into the foreseeable future.
In December 2014, the Company invested $3,500 in Physician Resource Management, Inc. in exchange for a 15% equity position. The Company is accounting for this investment under the cost method as the Company does not have significant influence over its operations.
|
9.DEBT
On April 1, 2015, in connection with the BioRx acquisition, the Company entered into a Second Amended and Restated Credit Agreement with General Electric Capital Corporation (“GE”), as agent and as a lender, the other lenders party thereto and the other credit parties party thereto, providing for an increase in the Company’s line of credit to $175,000, a fully drawn Term Loan A for $120,000 and a deferred draw term loan for an additional $25,000 (the “new credit facility”). The new credit facility also extended the maturity date to April 1, 2020. The new credit facility provides for the issuance of letters of credit up to $10,000 and swingline loans up to $15,000, the issuance and incurrence of which will reduce the availability of the line of credit. The new credit facility is guaranteed by substantially all of the Company’s subsidiaries and is collateralized by substantially all of the Company’s and its subsidiaries’ respective assets, with certain exceptions. In addition, the Company has pledged the equity of substantially all of its subsidiaries as security for the obligations under the new credit facility. The Company is required to maintain a depository bank account where money is collected and swept directly to the line of credit.
At September 30, 2015, the Company’s Term Loan A interest rate options were (i) LIBOR (as defined) plus 2.50% or (ii) Base Rate (as defined) plus 1.50%, and the Company’s line of credit and swingline loan interest rate options were (i) LIBOR (as defined) plus 2.00% or (ii) Base Rate (as defined) plus 1.00%. The Company is charged a monthly unused commitment fee ranging from 0.25% to 0.50% on the average unused daily balance.
The Company incurred deferred financing costs of $5,056 associated with the new credit facility, which were capitalized in “Deferred debt issuance costs” on the condensed consolidated balance sheet. These costs, along with previously unamortized deferred debt issuance costs, are being amortized to interest expense over the term of the new credit facility.
The new credit facility with GE contains certain financial and non-financial covenants. The Company was in compliance with all such covenants as of September 30, 2015.
As disclosed in Note 1, using proceeds received from its IPO in October 2014, the Company repaid all outstanding borrowings including existing indebtedness to certain current or former shareholders and employees of $19,824 and borrowings under the line of credit of $60,634.
|
10.SHARE-BASED COMPENSATION
A summary of the Company’s stock option activity as of and for the nine months ended September 30, 2015 is as follows:
|
|
|
|
|
|
Weighted |
|
|
|
||
|
|
|
|
Weighted |
|
Average |
|
|
|
||
|
|
|
|
Average |
|
Remaining |
|
Aggregate |
|
||
|
|
Number |
|
Exercise |
|
Contractual |
|
Intrinsic |
|
||
|
|
of Options |
|
Price |
|
Life |
|
Value |
|
||
|
|
|
|
|
|
(Years) |
|
|
|
||
Outstanding at December 31, 2014 |
|
7,217,331 |
|
$ |
7.54 |
|
6.9 |
|
$ |
142,262 |
|
Granted |
|
1,022,439 |
|
41.65 |
|
|
|
|
|
||
Repurchased |
|
(1,641,387 |
) |
5.44 |
|
|
|
|
|
||
Exercised |
|
(1,683,000 |
) |
5.20 |
|
|
|
|
|
||
Expired/cancelled |
|
(787,119 |
) |
16.13 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Outstanding at September 30, 2015 |
|
4,128,264 |
|
$ |
16.15 |
|
7.7 |
|
$ |
65,195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Exercisable at September 30, 2015 |
|
1,011,545 |
|
$ |
4.01 |
|
5.2 |
|
$ |
25,060 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company granted service-based awards of 631,396 options to purchase common stock to key employees under its 2014 Omnibus Incentive Plan during the nine months ended September 30, 2015. The options become exercisable in installments of 25% per year, beginning on the first anniversary of the grant date and each of the three anniversaries thereafter, and have a maximum term of ten years. The Company also granted performance-based awards of 391,043 options to purchase common stock to key employees under its 2014 Omnibus Incentive Plan during the nine months ended September 30, 2015. Such options will be earned or forfeited based upon the Company’s performance relative to specified revenue and adjusted earnings before interest, taxes, depreciation and amortization goals for the year ended December 31, 2015. The earned options, if any, will vest in four installments of 25%, with the first installment vesting upon Audit Committee confirmation of the satisfaction of the applicable performance goals, and the remaining installments vesting annually thereafter. These options also have a maximum term of ten years.
The 1,022,439 options to purchase common stock that were granted during 2015 and that are described in the above paragraph have a weighted average grant date fair value of $12.72 per option. The grant-date fair values of these stock option awards were estimated using the Black-Scholes-Merton option pricing model using the assumptions set forth in the following table:
Exercise price |
|
$39.26 - $48.72 |
|
Expected volatility |
|
25.82% - 26.70% |
|
Expected dividend yield |
|
0% |
|
Risk-free rate over the estimated expected life |
|
1.84% - 2.01% |
|
Expected life (in years) |
|
6.25 |
|
Estimating grant date fair values for stock options requires management to make assumptions regarding the expected volatility of value of the underlying common shares, the risk-free rate over the expected life of the stock options, and the date on which share-based payments will be settled. Expected volatility is based on an implied volatility for a group of industry-relevant healthcare companies as of the measurement date. Expected dividend yield is zero as the Company does not anticipate that any dividends will be declared during the expected life of the options. Risk-free rate is determined based upon U.S. Treasury rates over the estimated expected stock option lives. Expected life of the stock options is calculated using the simplified method (the midpoint between the end of the vesting period and the end of the maximum term) because the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its awards have been outstanding. If actual results differ significantly from these estimates and assumptions, share-based compensation expense, primarily with respect to future share-based awards, could be materially impacted.
In March 2015, the Company repurchased vested stock options to buy 1,641,387 shares of common stock from certain current employees, including certain executive officers, for cash consideration totaling $36,298. All repurchased stock options were granted under the Company’s 2007 Stock Option Plan. No incremental compensation expense was recognized as a result of these repurchases.
In April 2014, the Company repurchased vested stock options to buy 183,993 shares of common stock from certain current employees for cash consideration, totaling $2,300. No incremental compensation expense was recognized as a result of these redemptions.
In January 2014, the Company repurchased vested stock options to buy 239,768 shares of common stock from certain current employees for cash consideration, totaling $3,100. No incremental compensation expense was recognized as a result of these redemptions.
The Company recorded share-based compensation expense associated with stock options of $1,232 and $693 for the three months ended September 30, 2015 and 2014, respectively, and $2,389 and $1,828 for the nine months ended September 30, 2015 and 2014, respectively. Recorded share-based compensation expense for the three and nine months ended September 30, 2015 assumes achievement of certain performance-based goals.
During the fourth quarter of 2014, the Company granted 8,277 restricted share awards to its non-employee directors. The Company recorded share-based compensation expense associated with restricted stock awards of $38 and $113 for the three and nine months ended September 30, 2015, respectively.
For U.S. GAAP purposes, share-based compensation expense associated with stock options is based upon recognition of the grant date fair value over the vesting period of the option. For income tax purposes, share-based compensation tax deductions associated with stock option exercises and repurchases are based upon the difference between the stock price and the exercise price at time of exercise or repurchase. In instances where share-based compensation expense for tax purposes is in excess of share-based compensation expense for U.S. GAAP purposes, U.S. GAAP requires that the tax benefit associated with this excess expense be recorded to shareholders’ equity to the extent that it reduces cash taxes payable. During the three and nine months ended September 30, 2015, the Company recorded excess tax benefits related to share-based awards of $9,365 and $14,348, respectively. As of September 30, 2015, the Company has approximately $54,000 of excess share-based compensation expense remaining to offset against future taxable income. Therefore, at an estimated effective tax rate of 39.0%, the amount of excess tax benefits yet to be recognized by the Company as a reduction to cash taxes payable is approximately $21,000.
U.S. GAAP also requires that excess tax benefits related to share-based awards be reported as a decrease to cash flows from operating activities and as an increase to cash flows from financing activities. Therefore, the Company reported $14,348 of excess tax benefits related to share-based awards as a decrease to cash flows from operating activities and as an increase to cash flows from financing activities for the nine months ended September 30, 2015.
|
11.INCOME TAXES
As disclosed in Note 2, the Company changed its income tax status from an S corporation to a C corporation on January 23, 2014. Accordingly, on that date, the Company recorded a net deferred income tax liability of $2,965 and a corresponding charge to deferred income tax expense. This adoption impact, net of the impact of S corporation earnings from January 1, 2014 to January 22, 2014 which were not tax affected, resulted in a 47% effective tax rate for the nine months ended September 30, 2014. The Company’s effective tax rate for the nine months ended September 30, 2015 was 39%.
|
12.CONTINGENCIES
The Company is subject to claims and lawsuits that arise primarily in the ordinary course of business. Management believes that the disposition or ultimate resolution of such claims and lawsuits will not have a material adverse effect on the Company’s financial position, results of operations or cash flows.
|
13.REDEEMABLE CAPITAL STOCK
Several years prior to its IPO, the Company issued 11,050,000 shares of common stock to two shareholders that had certain redemption features which provided that upon the death of the shareholder or termination of his employment from the Company, all such outstanding shares owned by such shareholder would immediately be deemed to be offered for sale to the Company at an agreed-upon price meant to represent the then-current fair value of such shares. Due to this repurchase feature, the Company would be required to purchase the shares. Pursuant to this provision, the common shares were deemed to be mandatorily redeemable and, as such, were required to be reflected as a liability at their period end estimated fair value. Fair value was determined based on good faith estimates of the Company’s Board of Directors, in some cases with the assistance of independent third party valuations of the Company. The Company recognized a $6,916 and a $7,873 “Change in fair value of redeemable shares” during the three and nine months ended September 30, 2014, respectively.
In January 2014, the Company entered into a Redeemable Series A Preferred Stock Purchase Agreement with certain funds of T. Rowe Price Associates, Inc. (“T. Rowe”) under which the Company issued to T. Rowe 2,986,229 shares of Redeemable Series A Preferred Stock at a purchase price of $16.74 per share. The Company used $20,000 of this $50,000 investment for general corporate purposes inclusive of fees associated with this transaction, and the remaining $30,000 was distributed to holders of common stock ($26,900) and holders of options to acquire common stock ($3,100).
In April 2014, the Company entered into a Redeemable Series A Preferred Stock Purchase Agreement with certain funds of Janus Capital Management LLC (“Janus”) under which the Company issued to Janus 3,225,127 shares of Redeemable Series A Preferred Stock at a purchase price of $16.74 per share. The Company used $25,200 of this $54,000 investment for general corporate purposes inclusive of fees associated with this transaction, and the remaining $28,800 was distributed to holders of common stock ($26,500) and holders of options to acquire common stock ($2,300).
As disclosed in Note 1, immediately prior to the closing of the IPO, each share of the Company’s then-outstanding capital stock converted into one share of its newly-authorized shares of no par value common stock.
|
14.TERMINATION OF EXISTING STOCK REDEMPTION AGREEMENT
In August 2014, the Company issued 372,486 shares of common stock to a non-employee relative (and associated trusts) of the Company’s chief executive officer in connection with the termination of an existing stock redemption agreement. The Company recorded a charge of $4,842 during both the three and nine month periods ended September 30, 2014 associated with this transaction. The value of the issued shares was based on the Company’s initial public offering price of $13.00 per share.
|
15.INCOME PER COMMON SHARE
For the period January 23, 2014 through September 30, 2014, the Company computed net income per common share using the two-class method as its Redeemable Series A Preferred Stock met the definition of a participating security and thereby shared in the net income of the Company on a ratable basis with the common shareholders. The preferred stock’s portions of net income for the three and nine months ended September 30, 2014 were 16% and 13%, respectively.
The following table sets forth the computation of basic and diluted income per common share:
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
|
||||
Numerator: |
|
|
|
|
|
|
|
|
|
||||
Net income attributable to Diplomat Pharmacy, Inc. |
|
$ |
15,961 |
|
$ |
4,541 |
|
$ |
22,210 |
|
$ |
7,906 |
|
Less net income allocable to preferred shareholders |
|
— |
|
745 |
|
— |
|
1,062 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Net income allocable to common shareholders |
|
15,961 |
|
3,796 |
|
22,210 |
|
6,844 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Denominator: |
|
|
|
|
|
|
|
|
|
||||
Weighted average common shares outstanding, basic |
|
63,890,060 |
|
31,643,725 |
|
59,507,347 |
|
31,479,950 |
|
||||
Weighted average dilutive effect of stock options and restricted stock awards |
|
1,622,995 |
|
2,026,316 |
|
2,251,632 |
|
2,476,045 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Weighted average common shares outstanding, diluted |
|
65,513,055 |
|
33,670,041 |
|
61,758,979 |
|
33,955,995 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Net income per common share: |
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
0.25 |
|
$ |
0.12 |
|
$ |
0.37 |
|
$ |
0.22 |
|
Diluted |
|
$ |
0.24 |
|
$ |
0.11 |
|
$ |
0.36 |
|
$ |
0.20 |
|
Service-based stock options to purchase a weighted average of 615,504 and 270,421 common shares were excluded from the computation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2015, respectively, as inclusion of such options would be anti-dilutive. Performance-based stock options to purchase up to a weighted average of 678,234 and 550,512 common shares were excluded from the computation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2015, respectively, as none of the necessary conditions were satisfied as of September 30, 2015. Contingent consideration to issue up to 1,350,309 common shares was excluded from the computation of diluted weighted average common shares outstanding for both the three and nine months ended September 30, 2015 as none of the necessary conditions were satisfied as of September 30, 2015. Service-based stock options to purchase a weighted average of 679,629 and 579,653 common shares were excluded from the computation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2014, respectively, as inclusion of such options would be anti-dilutive. Performance-based stock options to purchase up to a weighted average of 871,293 and 826,103 common shares were excluded from the computation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2014, respectively, as none of the necessary conditions were satisfied as of September 30, 2014.
The effect of all Redeemable Series A Preferred Stock were excluded from the computation of diluted weighted average common shares outstanding for both the three and nine months ended September 30, 2014 as inclusion would be anti-dilutive.
|
Principles of Consolidation
The condensed consolidated financial statements include the accounts of Diplomat Pharmacy, Inc., its wholly-owned subsidiaries, and a 51%-owned subsidiary, formed in August 2014, which the Company controls (see Note 7). The Company also owns a 25% interest in a non-consolidated entity which is accounted for under the equity method of accounting since the Company does not control the entity but has the ability to exercise significant influence over its operating and financial policies. This equity method investment was fully impaired during the fourth quarter of 2014. An investment in an entity in which the Company owns less than 20% and does not have the ability to exercise significant influence is accounted for under the cost method.
Noncontrolling interest in a consolidated subsidiary in the condensed consolidated balance sheets represents the minority shareholders’ proportionate share of the equity in such subsidiary. Consolidated net income (loss) is allocated to the Company and noncontrolling interests (i.e., minority shareholders) in proportion to their percentage ownership.
All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.
Revenue Recognition
The Company recognizes revenue from prescription drug sales for home delivery at the time the drugs are shipped. At the time of shipment, the Company has performed substantially all of its obligations under its payor contracts and does not experience a significant level of returns or reshipments. If the Company administers a drug treatment regimen in a patient’s home, the Company recognizes revenue at the time of administration. Revenues from dispensing specialty prescriptions that are picked up by patients at an open door or retail pharmacy location are recorded at prescription adjudication, which approximates the fill date. Sales taxes are presented on a net basis (excluded from revenues and costs). Revenues generated from prescription drug sales were $941,533 and $592,410 for the three months ended September 30, 2015 and 2014, respectively, and $2,365,860 and $1,594,197 for the nine months ended September 30, 2015 and 2014, respectively.
The Company recognizes revenue from service, data and consulting services when the services have been performed and the earnings process is therefore complete. Revenues generated from service, data and consulting services were $5,380 and $3,119 for the three months ended September 30, 2015 and 2014, respectively, and $13,947 and $8,684 for the nine months ended September 30, 2015 and 2014, respectively.
New Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which will supersede the existing revenue recognition guidance under U.S. GAAP. The new standard focuses on creating a single source of revenue guidance for revenue arising from contracts with customers for all industries. The objective of the new standard is for companies to recognize revenue when it transfers the promised goods or services to its customers at an amount that represents what the company expects to be entitled to in exchange for those goods or services. In July 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606) Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 by one year to annual reporting periods beginning after December 15, 2017 for public entities. ASU 2014-09 may be applied either retrospectively or as a cumulative effect adjustment as of the date of adoption. Early adoption is not permitted. The Company is currently assessing the method under which it will adopt and the potential impact of adopting ASU 2014-09 on its financial position, results of operations, cash flows and/or disclosures.
In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Targets Could Be Achieved after the Requisite Service Period, requiring that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This ASU is effective within annual periods beginning on or after December 15, 2015, including interim periods within that reporting period. The Company does not expect the adoption of this guidance to have a significant impact on its financial position, results of operations, cash flows or disclosures.
In April 2015, the FASB issued ASU No. 2015-03, Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), and, in August 2015, the FASB issued ASU No. 2015-15, Interest — Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements - Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-15 then clarified that debt issuance costs related to a line-of-credit arrangement can be presented as an asset on the balance sheet, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. These ASUs are effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. An entity should apply this new guidance on a retrospective basis and is required to comply with applicable disclosures for a change in an accounting principle. These standards will result in a balance sheet reclassification and require related disclosure revisions in the Company’s financial statements.
In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective within annual periods beginning on or after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.
In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, requiring that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This ASU also requires an entity to present separately on the face of the income statement, or disclose in the notes to the financial statements, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This ASU is effective within annual periods beginning on or after December 15, 2015, including interim periods within that reporting period, and will be applied prospectively to measurement-period adjustments that occur after the effective date of this ASU.
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
|
||||
Net sales |
|
$ |
946,913 |
|
$ |
733,776 |
|
$ |
2,656,523 |
|
$ |
2,055,904 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to Diplomat Pharmacy, Inc. |
|
$ |
11,090 |
|
$ |
5,536 |
|
$ |
29,259 |
|
$ |
11,565 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share — basic |
|
$ |
0.17 |
|
$ |
0.13 |
|
$ |
0.47 |
|
$ |
0.27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per common share — diluted |
|
$ |
0.17 |
|
$ |
0.12 |
|
$ |
0.46 |
|
$ |
0.26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash at closing |
|
$ |
84,296 |
|
253,036 restricted common shares |
|
9,578 |
|
|
Receivable for post-closing adjustment |
|
(6,880 |
) |
|
|
|
|
|
|
|
|
$ |
86,994 |
|
|
|
|
|
|
Accounts receivable |
|
$ |
17,109 |
|
Inventories |
|
8,668 |
|
|
Prepaid expenses and other current assets |
|
7,514 |
|
|
Property and equipment |
|
88 |
|
|
Capitalized software for internal use |
|
17,000 |
|
|
Definite-lived intangible assets |
|
23,400 |
|
|
Accounts payable |
|
(25,761 |
) |
|
Accrued expenses — compensation and benefits |
|
(169 |
) |
|
Accrued expenses — other |
|
(6 |
) |
|
|
|
|
|
|
Total identifiable net assets |
|
47,843 |
|
|
Goodwill |
|
39,151 |
|
|
|
|
|
|
|
|
|
$ |
86,994 |
|
|
|
|
|
|
|
|
Useful |
|
Amount |
|
|
Physician relationships |
|
10 years |
|
$ |
15,000 |
|
Non-compete employment agreements |
|
5 years |
|
5,700 |
|
|
Favorable supply agreement |
|
1 year |
|
2,700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
23,400 |
|
|
|
|
|
|
|
|
Cash |
|
$ |
217,024 |
|
4,038,853 restricted common shares |
|
125,697 |
|
|
Contingent consideration at fair value |
|
41,000 |
|
|
|
|
|
|
|
|
|
$ |
383,721 |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
1,786 |
|
Accounts receivable |
|
38,946 |
|
|
Inventories |
|
5,546 |
|
|
Deferred income taxes |
|
382 |
|
|
Prepaid expenses and other current assets |
|
287 |
|
|
Property and equipment |
|
494 |
|
|
Definite-lived intangible assets |
|
181,700 |
|
|
Other noncurrent assets |
|
163 |
|
|
Accounts payable |
|
(25,088 |
) |
|
Accrued expenses — compensation and benefits |
|
(1,653 |
) |
|
Accrued expenses — other |
|
(852 |
) |
|
Deferred income taxes |
|
(9,117 |
) |
|
|
|
|
|
|
Total identifiable net assets |
|
192,594 |
|
|
Goodwill |
|
191,127 |
|
|
|
|
|
|
|
|
|
$ |
383,721 |
|
|
|
|
|
|
|
|
Useful |
|
Amount |
|
|
Patient relationships |
|
10 years |
|
$ |
130,000 |
|
Non-compete employment agreements |
|
5 years |
|
39,700 |
|
|
Trade names and trademarks |
|
8 years |
|
12,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
181,700 |
|
|
|
|
|
|
|
|
Cash |
|
$ |
52,267 |
|
716,695 restricted common shares |
|
12,000 |
|
|
Contingent consideration at fair value |
|
4,270 |
|
|
|
|
|
|
|
|
|
$ |
68,537 |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
668 |
|
Accounts receivable |
|
9,050 |
|
|
Inventories |
|
3,819 |
|
|
Prepaid expenses and other current assets |
|
204 |
|
|
Property and equipment |
|
697 |
|
|
Capitalized software for internal use |
|
25 |
|
|
Definite-lived intangible assets |
|
37,099 |
|
|
Accounts payable |
|
(3,638 |
) |
|
Accrued expenses — compensation and benefits |
|
(157 |
) |
|
Accrued expenses — other |
|
(865 |
) |
|
|
|
|
|
|
Total identifiable net assets |
|
46,902 |
|
|
Goodwill |
|
21,635 |
|
|
|
|
|
|
|
|
|
$ |
68,537 |
|
|
|
|
|
|
|
|
Useful |
|
Amount |
|
|
Patient relationships |
|
7 years |
|
$ |
24,000 |
|
Trade names and trademarks |
|
10 years |
|
8,700 |
|
|
Non-compete employment agreements |
|
5 years |
|
4,399 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
37,099 |
|
|
|
|
|
|
|
|
|
|
|
Asset / |
|
|
|
Valuation |
|
||
|
|
(Liability) |
|
Level 3 |
|
Technique |
|
||
September 30, 2015: |
|
|
|
|
|
|
|
||
Contingent consideration |
|
$ |
(44,281 |
) |
$ |
(44,281 |
) |
C |
|
|
|
|
|
|
|
|
|
||
December 31, 2014: |
|
|
|
|
|
|
|
||
Contingent consideration |
|
$ |
(11,691 |
) |
$ |
(11,691 |
) |
C |
|
|
|
Contingent |
|
|
Balance at January 1, 2015 |
|
$ |
(11,691 |
) |
BioRx acquisition |
|
(41,000 |
) |
|
Changes in fair value |
|
1,660 |
|
|
Payments |
|
6,750 |
|
|
|
|
|
|
|
Balance at September 30, 2015 |
|
$ |
(44,281 |
) |
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
||
|
|
2015 |
|
2014 |
|
||
Prescription medications, over-the-counter medications and medical supplies, and non-medical retail items |
|
$ |
153,286 |
|
$ |
110,464 |
|
Raw materials |
|
— |
|
208 |
|
||
Finished goods |
|
7 |
|
11 |
|
||
|
|
|
|
|
|
||
|
|
$ |
153,293 |
|
$ |
110,683 |
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2015 |
|
$ |
23,148 |
|
BioRx acquisition |
|
191,127 |
|
|
Burman’s acquisition |
|
39,151 |
|
|
|
|
|
|
|
Balance at September 30, 2015 |
|
$ |
253,426 |
|
|
|
|
|
|
|
|
September 30, 2015 |
|
December 31, 2014 |
|
||||||||||||||
|
|
Gross |
|
Accumulated |
|
Net |
|
Gross |
|
Accumulated |
|
Net |
|
||||||
Patient relationships |
|
$ |
159,100 |
|
$ |
(11,507 |
) |
$ |
147,593 |
|
$ |
29,100 |
|
$ |
(2,895 |
) |
$ |
26,205 |
|
Non-compete employment agreements |
|
50,399 |
|
(5,612 |
) |
44,787 |
|
4,999 |
|
(560 |
) |
4,439 |
|
||||||
Trade names and trademarks |
|
22,100 |
|
(2,082 |
) |
20,018 |
|
10,100 |
|
(575 |
) |
9,525 |
|
||||||
Physician relationships |
|
15,000 |
|
(438 |
) |
14,562 |
|
— |
|
— |
|
— |
|
||||||
Software licensing agreement |
|
2,647 |
|
— |
|
2,647 |
|
2,647 |
|
— |
|
2,647 |
|
||||||
Favorable supply agreement |
|
2,700 |
|
(787 |
) |
1,913 |
|
— |
|
— |
|
— |
|
||||||
Intellectual property |
|
2,157 |
|
— |
|
2,157 |
|
2,157 |
|
— |
|
2,157 |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
$ |
254,103 |
|
$ |
(20,426 |
) |
$ |
233,677 |
|
$ |
49,003 |
|
$ |
(4,030 |
) |
$ |
44,973 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
||
|
|
|
|
Weighted |
|
Average |
|
|
|
||
|
|
|
|
Average |
|
Remaining |
|
Aggregate |
|
||
|
|
Number |
|
Exercise |
|
Contractual |
|
Intrinsic |
|
||
|
|
of Options |
|
Price |
|
Life |
|
Value |
|
||
|
|
|
|
|
|
(Years) |
|
|
|
||
Outstanding at December 31, 2014 |
|
7,217,331 |
|
$ |
7.54 |
|
6.9 |
|
$ |
142,262 |
|
Granted |
|
1,022,439 |
|
41.65 |
|
|
|
|
|
||
Repurchased |
|
(1,641,387 |
) |
5.44 |
|
|
|
|
|
||
Exercised |
|
(1,683,000 |
) |
5.20 |
|
|
|
|
|
||
Expired/cancelled |
|
(787,119 |
) |
16.13 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
Outstanding at September 30, 2015 |
|
4,128,264 |
|
$ |
16.15 |
|
7.7 |
|
$ |
65,195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Exercisable at September 30, 2015 |
|
1,011,545 |
|
$ |
4.01 |
|
5.2 |
|
$ |
25,060 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price |
|
$39.26 - $48.72 |
|
Expected volatility |
|
25.82% - 26.70% |
|
Expected dividend yield |
|
0% |
|
Risk-free rate over the estimated expected life |
|
1.84% - 2.01% |
|
Expected life (in years) |
|
6.25 |
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
|
||||
Numerator: |
|
|
|
|
|
|
|
|
|
||||
Net income attributable to Diplomat Pharmacy, Inc. |
|
$ |
15,961 |
|
$ |
4,541 |
|
$ |
22,210 |
|
$ |
7,906 |
|
Less net income allocable to preferred shareholders |
|
— |
|
745 |
|
— |
|
1,062 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Net income allocable to common shareholders |
|
15,961 |
|
3,796 |
|
22,210 |
|
6,844 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Denominator: |
|
|
|
|
|
|
|
|
|
||||
Weighted average common shares outstanding, basic |
|
63,890,060 |
|
31,643,725 |
|
59,507,347 |
|
31,479,950 |
|
||||
Weighted average dilutive effect of stock options and restricted stock awards |
|
1,622,995 |
|
2,026,316 |
|
2,251,632 |
|
2,476,045 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Weighted average common shares outstanding, diluted |
|
65,513,055 |
|
33,670,041 |
|
61,758,979 |
|
33,955,995 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||
Net income per common share: |
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
0.25 |
|
$ |
0.12 |
|
$ |
0.37 |
|
$ |
0.22 |
|
Diluted |
|
$ |
0.24 |
|
$ |
0.11 |
|
$ |
0.36 |
|
$ |
0.20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|